FDA Neuro Panel Will Review Cyberonics, Confluent Postmarket Data

FDA's Neurological Devices Panel will consider post-approval study data for Cyberonics' implantable VNS Therapy for treatment-resistant depression and for Tyco/Confluent Surgical's DuraSeal cranial surgery sealant system Jan. 26, FDA announced Dec. 22